Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CACNA1F | O60840 | 6/20 | 0.49 |
| ▸ | CACNA1D | Q01668 | 6/20 | 0.49 |
| ▸ | CACNA1S | Q13698 | 6/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6689694 | 0.99 | ALDH1A1 (0.51) | ALDH1A1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL489551 | 0.95 | ALDH1A1 (0.51) | ALDH1A1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL489865 | 0.95 | MTOR (0.50) | ALDH1A1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL489543 | 0.90 | PPARA (0.51) | ALDH1A1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL489753 | 0.90 | ADORA3 (0.47) | ALDH1A1LMNAKDM4EMAPTMTOR | |
| SCHEMBL489303 | 0.88 | CACNA1C (0.47) | ALDH1A1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL489368 | 0.86 | LMNA (0.43) | ALDH1A1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL5408190 | 0.86 | PPARA (0.49) | ALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL6060939 | 0.85 | ADORA3 (0.41) | ALDH1A1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL17998996 | 0.85 | PPARA (0.50) | CACNA1FCACNA1DCACNA1SCACNA1CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1470108-B1 | 1,4-DIHYDROPYRIDINE AND PYRIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | VITTAL MALLYA SCIENT RES FOUNDATION (IN) | 2016-08-24 | — | — | EP | disclosed |
| US-8106062-B1 | Calcium channel blockers | DIAKRON PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-7235570-B2 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | VITTAL MALLYA SCIENTIFIC RESEARCH (IN) | 2007-06-26 | — | — | US | disclosed |
| US-7235570-B2 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | VITTAL MALLYA SCIENTIFIC RESEARCH (IN) | 2007-06-26 | — | — | US | disclosed |
| US-20050159455-A1 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | VITTAL MALLYA SCIENTIFIC RESEARCH (IN) | 2005-07-21 | — | — | US | disclosed |
| EP-1542683-A2 | CALCIUM CHANNEL BLOCKERS | Diakron Pharmaceuticals, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-6852742-B2 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2005-02-08 | — | — | US | disclosed |
| US-6852742-B2 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2005-02-08 | — | — | US | disclosed |
| WO-2004024153-A2 | CALCIUM CHANNEL BLOCKERS | DIAKRON PHARMACEUTICALS, INC. (US) | 2004-03-25 | — | — | WO | disclosed |
| US-20040006110-A1 | To modulate the activity of calcium channels, therapy of cardiovascular disease or neurological disorders, that are associated with calcium channels | Knobbe, Martens, Olson & Bear, LLP | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006110-A1 | To modulate the activity of calcium channels, therapy of cardiovascular disease or neurological disorders, that are associated with calcium channels | RYR2, ORAI1, RYR1 | ALDH1A1 3124/4885CACNA1F 10/4885CACNA1D 5/4885 |
| US-20050159455-A1 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | RYR1, RYR2, ORAI1 | ALDH1A1 2429/4885CACNA1F 17/4885CACNA1D 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.